A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer. A randomized phase II trial of 8 months of ...
Risk analysis of open vs. robotic assisted radical cystectomy. Randomized phase III clinical trial of neoadjuvant intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results